Nano Hydroxyapatite & Mineral Trioxide Aggregate Efficiently Promote Odontogenic Differentiation of Dental Pulp Stem Cells

BACKGROUND: There has been an urge to shift from conventional therapies to the more promising regenerative strategy since conventional treatment relies on synthetic materials to fill defects and replace missing tissues, lacking the ability to restore the tissues’ physiological architecture and function. AIM: The present study focused on the assessment of the role of two commonly used biomaterials namely; mineral trioxide aggregate (MTA) and nano hydroxy-apatite as promoters of odontogenic differentiation of dental pulp stem cells (DPSCs). METHODS: DPSCs were isolated, cultured in odontogenic media and divided into three groups; control group, MTA group and nanohydroxyapatite group. Odontogenic differentiation was assessed by tracing genes characteristic of different stages of odontoblasts via qRT-PCR. Calcific nodules formation was evaluated by Alizarin red staining. RESULTS: Results demonstrated that both MTA and nanohydroxyapatite were capable of enhancing odontogenic differentiation of DPSCs. CONCLUSION: Nano hydroxyapatite was found to have a higher promoting effect. However, in the absence of an odontogenic medium, MTA and nanohydroxyapatite could not enhance the odontogenic differentiation of DPSCs

Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial

A quadrivalent high-dose inactivated influenza vaccine (IIV4-HD) is licensed for adults 6565 y of age based on immunogenicity and efficacy studies. However, IIV4-HD has not been evaluated in adults aged 60\u201364 y. This study compared immunogenicity and safety of IIV4-HD with a standard-dose quadrivalent influenza vaccine (IIV4-SD) in adults aged 6560 y. This Phase III, randomized, modified double-blind, active-controlled study enrolled 1,528 participants aged 6560 y, randomized 1:1 to a single injection of IIV4-HD or IIV4-SD. Hemagglutination inhibition (HAI) geometric mean titers (GMTs) were measured at baseline and D 28 and seroconversion assessed. Safety was described for 180 d after vaccination. The primary immunogenicity objective was superiority of IIV4-HD versus IIV4-SD, for all four influenza strains 28 d post vaccination in participants aged 60\u201364 and 6565 y. IIV4-HD induced a superior immune response versus IIV4-SD in terms of GMTs in participants aged 60\u201364 y and those aged 6565 y for all four influenza strains. IIV4-HD induced higher GMTs in those aged 60\u201364 y than those aged 6565 y. Seroconversion rates were higher for IIV4-HD versus IIV4-SD in each age-group for all influenza strains. Both vaccines were well tolerated in participants 6560 y of age, with no safety concerns identified. More solicited reactions were reported with IIV4-HD than with IIV4-SD. IIV4-HD provided superior immunogenicity versus IIV4-SD and was well tolerated in adults aged 6560 y. IIV4-HD is assumed to offer improved protection against influenza compared with IIV4-SD in adults aged 6560 y, as was previously assessed for adults aged 6565 y

Stimuli-responsive multifunctional membranes of controllable morphology from poly(vinylidene fluoride)-graft-poly[2-(N,N-dimethylamino)ethyl methacrylate] prepared via atom transfer radical polymerization

10.1021/la801402uLangmuir242414151-14158LANG